intensity is significantly associated with increased relapse, decreased
disease-free survival (DFS), and decreased overall survival (OS) in acute
myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new
analysis of a phase III randomized clinical trial has shown.
A first-in-class immunoglobulin G4 (IgG4) antibody targeting CD47 has demonstrated durable responses when used in combination with rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or indolent lymphoma.